The FDA approved Merck’s redesigned drug container labels that include a new standardized format to improve readability and provide better information on product strength and differentiation. The changes were developed under Merck’s Label Standardization Project, which includes the revision of 34 containers for 16 solid oral drug products. Merck’s project evaluated the proposed label content and layout, selecting new packaging design, and obtaining regulatory approval to implement the new packaging design. Drugs affected by the revisions include: Cozaar, Crixivan, Hyzaar, Isentress, Janumet, Januvia, Mevacor, Noroxin, Prinivil, Prinizide, Propecia, Proscar, Singulair, Zocor, and Zolinza.
For more information visit www.fda.gov.